title: Clinical experience of K18 (IgG-melphalan) for five cases of refractory multiple myeloma.
authors.forename: R
authors.initials: R
authors.lastname: Kanamaru
authors.forename: A
authors.initials: A
authors.lastname: Wakui
authors.forename: C
authors.initials: C
authors.lastname: Ishioka
authors.forename: M
authors.initials: M
authors.lastname: Okuno
authors.forename: Y
authors.initials: Y
authors.lastname: Konishi
authors.forename: A
authors.initials: A
authors.lastname: Ishikawa
authors.forename: H
authors.initials: H
authors.lastname: Shibata
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage; D000922:Immunotoxins / Q000627:therapeutic use*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage
chemical_list: D007074:Immunoglobulin G; D000922:Immunotoxins; D011239:Prednisolone; D008558:Melphalan